When the FDA Steps Back: Why Selling Digital Health Just Got Harder

Why this issue exists

In January 2026, the FDA updated its General Wellness: Policy for Low Risk Devices guidance.

Most headlines framed it as regulatory relief. Many founders read it as permission to move faster. Most buyers read it as a transfer of liability. Because when the FDA steps back, the market steps in. And markets don't regulate; they evaluate.

Curb moment: The guardrails moved. The accountability didn't.

What the FDA actually did

The updated guidance clarified and expanded what qualifies as "low-risk," particularly for AI-enabled software, wearables, and behavior-influencing technologies. The signal from the administration was clear: remove barriers for AI innovation.

But if you read past the headlines, the burden of proof has actually shifted:

Intended use still matters: Labeling must include plain-language descriptions of underlying algorithms sufficient for clinicians to understand the basis of any recommendation.

Claims still matter: The FDA didn't endorse these products; it simply stopped standing in front of them.

Accuracy is your problem: Experts warn that AI "hallucinations" and biases are now the manufacturer's liability, not the regulator's.

Curb moment: You're allowed to play. You still own the outcome.

The Primary Buying Signal: Trust Replaces Regulation

As FDA oversight lightens, trust becomes the gating factor for capital allocation. Providers, payers, and investors are no longer asking if you are compliant; they are asking:

Who validated this in a real clinical setting?

Who owns the downstream risk when the model guesses wrong?

What happens to patient data privacy when consumer devices aren't covered by HIPAA?

These are no longer just legal questions. They are commercial deal-killers.

Curb moment: Low-risk devices still create high-risk meetings.

The Secondary Signal: Health Systems Are Becoming the Validators

A clear pattern is emerging: success in 2026 requires the endorsement or co-development of a major health system.

Rohit Chandra, Chief Digital Officer at Cleveland Clinic, notes that they view themselves as a "healthcare company, not a technology company." They are moving away from "shiny pilots" to focus on "bending" transformative technology to their specific environment through deep partnerships.

This marks a definitive shift from selling to health systems → building with health systems.

Curb moment: The model is impressive. The liability is still a group project.

A Familiar Warning: The RPM COVID Effect

We've seen this movie before. During COVID, Remote Patient Monitoring (RPM) exploded as barriers vanished overnight. But execution didn't keep up — client success teams were thin, customer support broke, and trust eroded.

In 2026, buyers are optimizing for:

Operational UX: Redesigning roles, not just automating tasks.

Mature Support: Real human accountability behind the "Agentic AI."

Audit Trails: Repeatable workflows that allow AI to drive outcomes across functions.

Curb moment: Speed without discipline is just noise.

Commercial Reality: Why Selling Just Got Harder

While the "One Big Beautiful Bill" (OBBB) Act promises infrastructure investment, it arrives alongside a $1 Trillion cut to Medicaid over 10 years. This is creating an "Efficiency Reset" across the industry.

The Layoff Signal: Even as they invest in AI "Factories," the giants are cutting to survive:

Bayer: 12,000+ jobs cut to reduce bureaucracy.

Novo Nordisk: ~9,000 cuts to generate $1.25 Billion in savings.

Merck: ~6,000 cuts as part of a multi-year restructuring.

Curb moment: Less regulation. More math.

Sales Corner: The 2026 Playbook

In a market defined by Governed Commercial Execution, the best teams are winning by helping buyers "say yes safely."

Stop selling "FDA-exempt" as a feature: It's a liability signal to a CFO.

Lead with Governance: Define exactly who owns the risk in the "group project."

Speed is the Moat: Use AI to compress your own sales and contract cycles. If an RFP takes weeks, you've already lost.

Curb moment: Selling confidence still beats selling capability.

SigCom Interpretation

The FDA didn't make digital health easier to sell; it made the market more honest. The companies that scale won't be the loudest — they'll be the ones that can prove their results are auditable and repeatable.

The Lab Note

This isn't just about the signals I'm seeing — it's about the ones you're experiencing. If you're building, buying, or selling right now, I'd love to hear: Are health systems asking to co-develop before they buy? Is "Trust" showing up earlier in your RFPs than "ROI"?

No hype. No promotion. Just signals.